CRISPR Therapeutics AG (CRSP) stock
CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$42.24−0.38 (-0.89%)
Close on Nov 13, 2026Market cap $4.08BP/E –Yield –
CRISPR Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
CRISPR Therapeutics's operating margin for the twelve months ending Sep 30, 2026 was -2114.8%. For fiscal 2025 it was -18933.6%, against -1250.4% the year before. The highest annual figure on record is 40.8% in fiscal 2021.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -18933.6% | −17683.3 |
| FY2024 | Dec 31, 2024 | -1250.4% | −1190.4 |
| FY2023 | Dec 31, 2023 | -60.0% | +56130.5 |
| FY2022 | Dec 31, 2022 | -56190.4% | −56231.2 |
| FY2021 | Dec 31, 2021 | 40.8% | +49336.4 |
| FY2020 | Dec 31, 2020 | -49295.5% | −49311.7 |
| FY2019 | Dec 31, 2019 | 16.1% | +5103.9 |
| FY2018 | Dec 31, 2018 | -5087.8% | −4930.1 |
| FY2017 | Dec 31, 2017 | -157.7% | +1161.6 |
| FY2016 | Dec 31, 2016 | -1319.3% | +9097.3 |
| FY2015 | Dec 31, 2015 | -10416.6% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -1026.5% | +13828.3 |
| Q2 FY2026 | Jun 30, 2026 | -1151.8% | +24557.1 |
| Q1 FY2026 | Mar 31, 2026 | -8933.3% | +8225.5 |
| Q4 FY2025 | Dec 31, 2025 | -17912.5% | −17731.5 |
| Q3 FY2025 | Sep 30, 2025 | -14854.8% | +3439.2 |
| Q2 FY2025 | Jun 30, 2025 | -25709.0% | +3548.3 |
| Q1 FY2025 | Mar 31, 2025 | -17158.8% | +10735.4 |
| Q4 FY2024 | Dec 31, 2024 | -181.0% | −215.5 |
| Q3 FY2024 | Sep 30, 2024 | -18294.0% | −18158.0 |
| Q2 FY2024 | Jun 30, 2024 | -29257.3% | −29192.8 |
| Q1 FY2024 | Mar 31, 2024 | -27894.2% | +2164455.8 |
| Q4 FY2023 | Dec 31, 2023 | 34.6% | +194064.4 |
| Q2 FY2023 | Jun 30, 2023 | -136.0% | +115851.3 |
| Q1 FY2023 | Mar 31, 2023 | -64.5% | +18655.9 |
| Q4 FY2022 | Dec 31, 2022 | -2192350.0% | −2191220.5 |
| Q3 FY2022 | Sep 30, 2022 | -194029.8% | −178392.8 |
| Q2 FY2022 | Jun 30, 2022 | -115987.3% | −116072.0 |
| Q1 FY2022 | Mar 31, 2022 | -18720.4% | +2530.6 |
| Q4 FY2021 | Dec 31, 2021 | -1129.5% | +27995.1 |
| Q3 FY2021 | Sep 30, 2021 | -15637.0% | +46794.7 |
| Q2 FY2021 | Jun 30, 2021 | 84.7% | +183468.8 |
| Q1 FY2021 | Mar 31, 2021 | -21251.0% | +25619.0 |
| Q4 FY2020 | Dec 31, 2020 | -29124.6% | −29138.9 |
| Q3 FY2020 | Sep 30, 2020 | -62431.8% | −62497.4 |
| Q2 FY2020 | Jun 30, 2020 | -183384.1% | −166093.8 |
| Q1 FY2020 | Mar 31, 2020 | -46870.1% | −32107.0 |
| Q4 FY2019 | Dec 31, 2019 | 14.3% | +39343.0 |
| Q3 FY2019 | Sep 30, 2019 | 65.7% | +8845.8 |
| Q2 FY2019 | Jun 30, 2019 | -17290.3% | −13863.2 |
| Q1 FY2019 | Mar 31, 2019 | -14763.1% | −12775.1 |
| Q4 FY2018 | Dec 31, 2018 | -39328.7% | −39331.7 |
| Q3 FY2018 | Sep 30, 2018 | -8780.1% | −7792.7 |
| Q2 FY2018 | Jun 30, 2018 | -3427.0% | −2832.2 |
| Q1 FY2018 | Mar 31, 2018 | -1988.0% | −1220.6 |
| Q4 FY2017 | Dec 31, 2017 | 3.0% | +1082.8 |
| Q3 FY2017 | Sep 30, 2017 | -987.4% | – |
| Q2 FY2017 | Jun 30, 2017 | -594.8% | – |
| Q1 FY2017 | Mar 31, 2017 | -767.4% | – |
| Q4 FY2016 | Dec 31, 2016 | -1079.8% | – |
See a number that looks wrong?